Effects of prolonged versus short-term exposure paclitaxel (Taxol®) on human tumor colony-forming units

Anti-Cancer Drugs

Volumn 8, Issue 4, 1997, Pages 379-385

  Raymond, Eric ^a   Hanauske, Axel ^a   Faivre, Sandrine ^a   Izbicka, Elzbieta ^a   Clark, Gary ^a   Rowinsky, Eric K ^a   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

Cell proliferation; Chemotherapy; Continuous infusion; Docetaxel; Taxanes

Indexed keywords

DOCETAXEL; PACLITAXEL;

ARTICLE; BIOPSY; BREAST CANCER; CELL CULTURE; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; OVARY CANCER; PRIORITY JOURNAL;

EID: 0030974772     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199704000-00011     Document Type: Article

References (38)

1. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has angiogenic activity. Clin Cancer Res 1996; 2: 1843-9.
2. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093-100.
3. Schiff PB, Horwitz S. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561-5.
4. Diaz JF, Andren JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere; reversibility, ligand stoichiometry and competition. Biochemistry 1993; 32: 2747-55.
5. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-6.
6. Jordon MA, Wendell K, Gardiner S, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56: 816-25.
7. Lopes NM, Adams, EG, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32: 235 42.
8. Slichenmyer WJ, Von Hoff DD. Taxol: a new and effective anti-cancer drug. Anti-Cancer Drugs 1991; 2: 519-30.
9. Dorr RT, Von Hoff DD. Cancer chemotherapy handbook. Norwalk, CT: Appleton & Lange 1994.
10. Bhalla K, Ibrado AM, Tourkina E, et al. Taxol induces intranucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993; 7: 563-8.
11. Hanauske A-R, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD. Effects of taxotere and taxol on in vitro colony formation of freshly expanted human tumor cells. Anti-Cancer Drugs 1992; 3: 121-4.
12. Arbuck SA, Blaylock B. Dose and schedule issues. In: McGuire WP, Rowinsky EK, eds. Paclitaxel in cancer treatment. New York: Marcel Dekker 1995: 151-73.
13. Gianni L. Theoretical and practical aspects of paclitaxel scheduling. Ann Oncol 1995; 6: 861-3.
14. Rowinsky EK. The taxanes: dosing and scheduling considerations. Oncology 1997; in press.
15. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995; 1: 599-606.
16. Rowinsky EK. Clinical pharmacology of taxol. J Natl Cancer Inst Monogr 1993; 15: 25-37.
17. Alberts D, Chen H. Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: Salmon SE, ed. Human tumor stem cells. New York: Alan R Liss 1980: 351-9.
18. Salmon S, Hamburger A, Soehnlen B, et al. Quantification of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 1978; 298: 1321-7.
19. Von Hoff D. Human tumor stem cell assay. Curr Therapy Hematol Oncol 1987; 3: 365-7.
20. Von Hoff D, Clark G, Stogdill B, et al. Prospective clinical trial of human tumor cloning system. Cancer Res 1983; 43: 1926-31.
21. Von Hoff D, Sandback J, Clark G, et al. Selection of cancer chemotherapy for patient by an in vitro assay versus a clinician. J Natl Cancer Inst 1990; 82: 110-6.
22. Shoemaker R, Wolpert-DeFilippes M, Kern D, et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 1985; 45: 2145-53.
23. Helson L, Helson C, Malik S, et al. A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells. Anti-Cancer Drugs 1993; 4: 487-90.
24. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992; 30: 444-50.
25. Zhan Z, Kang Y-K, Regi J, et al. Taxol resistance: in vitro and in vivo studies in breast cancer and lymphoma. Proc Am Ass Cancer Res 1993; 34: A215.
26. Georgiadis MS, Russel E, Johnson BE. Prolonging the exposure of human lung cancer cell lines to paclitaxel increases the cytotoxicity. Proc Int Ass Study Lung Cancer 1994; 11: A95.
27. Nusbaum NJ, Abraham T. Paclitaxel effect on leukemia cell line: importance of paclitaxel concentration. Anti-Cancer Drugs 1995; 6: 427-31.
28. Rowinsky EK, Wright M, Monsarrat B, Lesser GJ, Donehower RC. Taxol: pharmacology, metabolism, and clinical implications. Cancer Surv 1993; 17: 283-304.
29. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995; 22 (suppl 6): 16-23.
30. Walle T, Walle UK, Kumar GN, Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Met Disp 1995; 23: 506-12.
31. Gaver RC, Deeb G, Willey T, et al. The disposition of paclitaxel (taxol) in the rat. Proc Am Ass Cancer Res 1993; 34: A390.
32. Eiseman JL, Eddington ND, Leslie J, et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 1994; 34: 465-71.
33. 3H]paclitaxel in rats. Cancer Chemother Pharmacol 1997; in press.
34. Spriggs DR, Tondini C. Taxol administered as a 120-hour infusion. Invest New Drugs 1992; 10: 275-8.
35. Wilson WH, Bergs SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621-9.
36. Lokich J, Anderson N, Bern M, et al. Multi-day fractionated administration schedule for paclitaxel. Ann Oncol 1995; 6: 883-5.
37. Eisenhauer E, ten Bokke Huinink W, Swenerton KD, et al. European-Canadian randomized trial of taxol in relapsed ovarian cancer: high versus low dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
38. Markman MM, Rowinsky E, Hakes T, et al. Phase I study of taxol administered by intraperitoneal route. A Gynecology Oncology Group Study. J Clin Oncol 1992; 10: 1485-91.